LBL Lattice Biologics Ltd

Financial results to be released after market on Tuesday, August 29, 2017

The conference call dial-in number in the release dated August 25, 2017, should be: 863-208-0120 (instead of 213-416-1560).

The corrected release reads:

NOTICE OF LATTICE BIOLOGICS LTD. THIRD QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL

Financial results to be released after market on Tuesday, August 29, 2017

Lattice Biologics Ltd. (TSX -V: LBL) (OTCQB: LBLTF) (the “Company”) announced today it will release its third quarter 2017 financial results after market on Tuesday, August 29, 2017. Following this, Guy Cook, Chief Executive Officer, and Cheryl Farmer, Chief Financial Officer, will host a conference call at 9:30 a.m. EDT on Wednesday, August 30, 2017, to review the results. A question and answer session will follow the corporate update.

CONFERENCE CALL DETAILS:

  DATE: Wednesday, August 30, 2017 TIME:

9:30 a.m. Eastern Time

DIAL-IN NUMBER:

(863) 208-0120

ATTENDEE PIN: 286 6963#  

Register for the online webinar for full meeting functionality:

http://www.anymeeting.com/LatticeBiologics

  A recording of the call will be archived on the Company’s website at:

http://www.latticebiologics.com/webinars/

 

Subscribe to Lattice News UpdatesFollow us on Twitter: @LatticeBio

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the “safe harbor” provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “planned,” “potential,”“ future,” “expected,” “could,” “possible,”“ goal,” “intends,” “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to the Transaction, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170825005044/en/

Lattice Biologics Ltd.Cheryl Farmer, 480-563-0800CFONews@LatticeBiologics.comwww.LatticeBiologics.com